Biological agents targeting interleukin-18

Drug News and Perspectives

Volumn 20, Issue 8, 2007, Pages 485-494

  Jelusic, Marija ^a,b   Lukic, Ivan Kresimir ^a   Batinic, Drago ^a  

^a UNIVERSITY OF ZAGREB   (Croatia)

^b KBC Zagreb   (Croatia)

Author keywords

[No Author keywords available]

Indexed keywords

ABT 325; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 1; INTERLEUKIN 18; INTERLEUKIN 18 ANTIBODY; INTERLEUKIN 18 BINDING PROTEIN; INTERLEUKIN 18 RECEPTOR; INTERLEUKIN 1BETA; MESSENGER RNA; MONOCLONAL ANTIBODY; PRALNACASAN; PURINERGIC P2X7 RECEPTOR; TRANSCRIPTION FACTOR AP 1; TRANSCRIPTION FACTOR PU 1; TUMOR NECROSIS FACTOR ALPHA ANTIBODY; UNCLASSIFIED DRUG;

AUTOIMMUNE DISEASE; CHRONIC INFLAMMATION; CROHN DISEASE; CYTOKINE PRODUCTION; CYTOKINE RELEASE; DIARRHEA; HUMAN; IMMUNE RESPONSE; INFLAMMATORY DISEASE; INNATE IMMUNITY; INSULIN DEPENDENT DIABETES MELLITUS; JUVENILE RHEUMATOID ARTHRITIS; LYMPHOCYTE DIFFERENTIATION; MULTIPLE SCLEROSIS; NAUSEA; NONHUMAN; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; PROTEIN STRUCTURE; REVIEW; RHEUMATOID ARTHRITIS; SYSTEMIC LUPUS ERYTHEMATOSUS;

ANIMALS; BIOLOGICAL PRODUCTS; HUMANS; IMMUNE SYSTEM DISEASES; INTERLEUKIN-18; MODELS, IMMUNOLOGICAL; T-LYMPHOCYTE SUBSETS;

EID: 38749123525     PISSN: 02140934     EISSN: None     Source Type: Journal    
DOI: 10.1358/dnp.2007.20.8.1157617     Document Type: Review

References (176)

1. Okamura, H., Kawaguchi, K., Shoji, K. and Kawade, Y. High-level induction of γ interferon with various mitogens in mice pretreated with Propionibacterium acnes. Infect Immun 1982, 38(2): 440-3.
2. Nolan, K.F., Greaves, D.R., Waldmann, H. et al. The human interleukin 18 gene IL18 maps to 11q22.2-q22.3, closely linked to the DRD2 gene locus and distinct from mapped IDDM loci. Genomics 1998, 51(1): 161-3.
3. Tone, M., Thompson, S.A., Tone, Y. et al. Regulation of IL-18 (IFN-γ-inducing factor) gene expression. J Immunol 1997, 159(12): 6156-63.
4. Puren, A.J., Fantuzzi, G., Dinarello, C.A. Gene expression, synthesis, and secretion of interleukin 18 and interleukin 1 β are differentially regulated in human blood mononuclear cells and mouse spleen cells. Proc Natl Acad Sci USA 1999, 96(5): 2256-61.
5. Kalina, U., Ballas, K., Koyama, N. et al. Genomic organization and regulation of human interleukin-18 gene. Scand J Immunol 2000, 52(6): 525-30.
6. Kim, Y.M., Kang, H.S., Paik, S.G. et al. Roles of IFN consensus sequence binding protein and PU.1 in regulating IL-18 gene expression. J Immunol 1999, 163(4): 2000-7.
7. Koyama, N., Hoelzer, D. and Ottmann, O.G. Regulation of human Il-18 gene expression: interaction of PU.1 with GC-box binding protein is involved in human Il-18 expression in myeloid cells. Eur J Immunol 2004, 34(3): 817-26.
8. Kim, Y.M., Im, J.Y., Han, S.H. et al. IFN-γ up-regulates IL-18 gene expression via IFN consensus sequence-binding protein and activator protein-1 elements in macrophages. J Immunol 2000, 165(6): 3198-205.
9. Bazan, J.F., Timans, J.C. and Kastelein, R.A. A newly defined interleukin-1? Nature 1996, 379(6566): 591.
10. Ushio, S., Namba, M., Okura, T. et al. Cloning of the cDNA for human IFN-γ-inducing factor, expression in Escherichia coli, and studies on the biologic activities of the protein. J Immunol 1996, 156(11): 4274-9.
11. McInnes, I.B., Gracie, J.A., Leung, B.P. et al. Interleukin 18: A pleiotrope participant in chronic inflammation. Immunol Today 2000, 21(7): 312-5.
12. Gu, Y., Kuida, K., Tsutsui. H. et al. Activation of interferon-γ inducing factor mediated by interleukin-1β converting enzyme. Science 1997, 275(5297): 206-9.
13. Ghayur, T, Banerjee, S., Hugunin, M. et al. Caspase-1 processes IFN-γ-inducing factor and regulates LPS-induced IFN-γ production. Nature 1997, 386(6625): 619-23.
14. Sugawara, S., Uehara, A., Nochi, T. et al. Neutrophil proteinase 3-mediated induction of bioactive IL-18 secretion by human oral epithelial cells. J Immunol 2001, 167(11): 6568-75.
15. Gracie, J.A. Interleukin-18 as a potential target in inflammatory arthritis. Clin Exp Immunol 2004, 136(3): 402-4.
16. Kato, Z., Jee, J., Shikano, H. et al. The structure and binding mode of interleukin-18. Nat Struct Biol 2003, 10(11 ): 966-71.
17. Gracie, J.A., Robertson, S.E. and McInnes, I.B. Interleukin-18. J Leukoc Biol 2003, 73(2): 213-24.
18. Cheung, H., Chen, N.J., Cao, Z. et al. Accessory protein-like is essential for IL-18-medialed signaling. J Immunol 2005, 174(9): 5351-7.
19. Born, T.L., Thomassen, E., Bird, T.A. and Sims, J.E. Cloning of a novel receptor subunit, AcPL, required for interleukin-18 signaling. J Biol Chem 1998, 273(45): 29445-50.
20. Torigoe, K., Ushio, S., Okura, T. et al. Purification and characterization of the human interleukin-18 receptor. J Biol Chem 1997, 272(41): 25737-12.
21. Gerdes, N., Sukhova, G.K., Libby, P. et al. Expression of interleukin (IL)-18 and functional IL-18 receptors on human vascular endothelial cells, smooth muscle cells, and macrophages: Implications for atherogenics. J Exp Med 2002, 195(2): 245-57.
22. Nakanishi, K., Yoshimoto, T., Tsutsi, H. and Okamura, H. Interleukin-18 regulates both Th1 and Th2 responses. Annu Rev Immunol 2001, 19:423-74.
23. Leung, B.P., Culshaw, S., Gracie, J.A. et al. A role for IL-18 in neutrophil activation. J Immunol 2001, 167(5): 2879-86.
24. Tsutsui, H., Yoshimoto, T., Hayashi, N., Mizutani, H. and Nakanishi, K. Induction of allergic inflammation by interleukin-18 in experimental animal models. Immunol Rev 2004, 202: 115-38.
25. + T cells in the induction of immunoglobulin E antibodies in response to interleukin-18 treatment of mice. J Exp Med 2003, 197(8): 997-1005.
26. Kato, Z., Jee, J., Shikano, H. et al. The structure and binding mode of interleukin 18. Nat Struct Biol 2003, 10(11): 966-71.
27. Adachi, O., Kawai, T., Takeda, K. et al. Targeted disruption of the MyD88 gene results in loss of IL-1 and IL-18 mediated function. Immunity 1998, 9(1): 143-50.
28. Wesche, H., Henzel, W.J., Shilinglaw, W., Li, S. and Cao, Z. MyD88: An adapter that recruits IRAK to the IL-1 receptor complex. Immunity 1997, 7(6): 837-47.
29. Kanakaraj, P., Ngo, K., Wu, Y. et al. Defective interleukin (IL)-18 mediated natural killer and T helper cell type 1 responses in IL-1 receptor associated kinase (IRAK)-deficient mice. J Exp Med 1999, 189(7): 1129-38.
30. Kojima, H., Takeuchi, H., Ohta, T. et al. Interleukin-18 activates the IRAK-TRAF6 pathway in mouse EL-4 cells. Biochem Biophya Res Commun 1998, 244(1): 183-6.
31. Cao, Z., Xiong, J., Takeuchi, M., Kurama, T. and Goeddel, D.V. TRAF6 is a signal transducer for interleukin-1. Nature 1996, 383(6599): 443-6.
32. Matsumoto, S., Tsuji-Takayama, K., Aizawa, Y. et al. Interleukin-18 activates NF-κB in murine T helper type 1 cells. Biochem Viophys Res Commun 1997, 234(2): 454-57.
33. Kojima Haizawa, Y. Yanai, Y. et al. An essential role for NF-κB in IL-18-induced IFN-γ expression in KG-1 cells. J Immunol 1999, 162: 5063-9.
34. Andrassy, M., Igwe, J., Autschbach, F. et al. Posttranslationally modified proteins as mediators of sustained intestinal inflammation. Am J Pathol 2006, 169(4): 1223-37.
35. Mühl, H. and Pfeilschifter, J. Interleukin-18 bioactivity: A novel target for immunopharmagological anti-inflammatory intervention. Eur J Pharmacol 2004, 500(1-3): 63-71.
36. Paulukat, J., Bosmann, M., Nold, M. et al. Expression and release of IL-18 binding protein in response to IFN-γ. J Immunol 167(12): 7038-43.
37. Mühl, H., Kampfer, H., Bosmann, M. et al. lnterferon-γ mediates gene expression of interleukin-18 binding protein in non-leukocytic cells. Biochem Biophys Res Commun 2000, 267(3): 960-3.
38. Hurgin, V., Novick, D. and Rubinstein, M. The promoter of IL-18 binding protein activation by an IFN-γ-induced complex of IFN regulatory factor 1 and CCAAT/enhancer binding protein-β. Proc Natl Acad Sci U S A 2002, 99(26): 16957-62.
39. Möller, B., Paulukat, J., Nold, M. et al. Interferon-γ induces expression of interleukin-18 binding protein in fibroblast-like synoviocytes. Rheumatology (Oxford) 2003, 42(3): 442-5.
40. Pan, G., Risser, P., Mao, W. et al. IL-1H, an interleukin 1-related protein that binds IL-18 receptor/IL-1Rrp. Cytokine 2001, 13(1): 1-7.
41. Yoshimoto, T., Takeda, K., Tanaka, T. et al. IL-12 up-regulates IL-18 receptor expression on T cells, Th1 cells, and B cells: Synergism with IL-18 for IFN-γ production. J Immunol 1998, 161(7): 3400-7.
42. Okamura, H., Tsutsi, H., Komatsu, T. et al. Cloning of a new cytokine that induces IFN-γ production by T cells. Nature 1995, 378(6552): 88-91.
43. Dao, T., Mehal, W.Z. and Cripse, I.N. IL-18 augments perforin-dependent cytotoxicity. J Immunol 1998, 161(5): 2217-22.
44. Micallef, M.J., Ohtsuki, T., Kohno, K. et al. Interferon-γ- inducing factor enhances T helper 1 cytokine production by stimulated human T cells: Synergism with interleukin-12 for interferon-γ production. Eur J Immunol 1996, 26(7): 1647-51.
45. Hoshino, T., Wiltrout, R.H. and Young, H.A. IL-18 is a potent coinducer of IL-13 in NK and T cells: A new potential role for IL-18 in modulating the immune response. J Immunol 1999, 162(9): 5070-77.
46. Hoshino, T., Yagita, H., Ortlado, J.R., Wiltrout, R.H. and Young, H.A. In vivo administration of IL-18 can induce IgE production through Th2 cytokine induction and up-regulation of CD40 ligand (CD154) expression on CD4+ T cells. Eur J Immunol 2000, 30(7): 1998-2006.
47. Münder, M., Mallo, M., Eichmann, K. et al. Murine macrophages secrete interferon γ upon combined stimulation with interleukin (IL)-12 and IL-18: a novel pathway of autocrine macrophages activation. J Exp Med 1998, 187(12): 2103-8.
48. Reddy P. Interleukin-18: Recent advances. Curr Opin Hematol 2004, 11(6): 405-10.
49. Okamura, H., Tsutsui, H., Kashiwamura, S.I., Yoshimoto, T. and Nakanishi, K. Interleukin-18: a novel cytokine that augments both innate and acquired immunity. Adv Immunol 1998, 70: 281-312.
50. Gillespie, M.T. and Horwood, N.J. Interleukin-18 perspectives on the newest interleukin. Cytokine Growth Factor Rev 1998, 9(2): 109-16.
51. Yoshimoto, T., Tsutsui, H., Tominaga, K. et al. IL-18, although antiallergic when administered with IL-12, stimulates IL-4 and histamine release by basophils. Proc Natl Acad Sci U S A 1999, 96(24): 13962-66.
52. Andrews, D.M., Scalzo, A.A., Yokoyama, W.M. et al. Functional interactions between dendritic cells and NK cells during viral infection. Nat Immunol 2003, 4(2): 175-81.
53. Dinarello, C.A. and Fantuzzi, G. Interleukin-18 and host defence against infection. J Infect Dis 2003, 187: 370-84.
54. Guidotti, L.G., Rochford, R. and Chung, J. Viral clearance without destruction of infected cells during acute HBV infection. Science 1999, 284(5415): 825-29.
55. Kimura, K., Kakimi, K., Wieland, S., Guidotti, L.G. and Chisari, F.V. Interleukin-18 inhibits hepatitis B virus replication in the livers of transgenic mice. J Virol 2002, 76(21): 10702-7.
56. Kinjo, Y., Kawakami, K., Uezu, K. et al. Contribution of IL-18 to Th1 response and host defense against infection by Mycobacterium tuberculosis: a comparative study with IL-12p40. J Immunol 2002, 169(1): 323-9.
57. Neighbors, M., Xu, X., Barrat, F. et al. A critical role for interleukin 18 in primary and memory effector responses to Listeria monocytogenes that extends beyond its effects on Interferon γ production. J Exp Med 2001, 194(3): 343-54.
58. Kawakami, K., Koguchi, Y., Qureshi, M.H. et al. IL-18 contributes to host resistance against infection with Cryptococcus neoformans in mice with defective IL-12 synthesis through induction of IFN-γ production by NK cells. J Immunol 2000; 165(2): 941-7.
59. Ohkusu, K., Yoshimoto, T., Takeda, K. et al. Potentiality of interleukin-18 as a useful reagent for treatment and prevention of Leishmania major infection. Infect Immunol 2000, 68: 2449-56.
60. Singh, R.P., Kashiwamura, S., Rao, P. et al. The role of IL-18 in blood-stage immunity against murine malaria Plasmodium yoelii 265 and Plasmodium berghei ANKA. J Immunol 2002, 168(9): 4674-81.
61. Liew, F.Y, Wei. X.Q. and McIness, L.B. Role of interleukin 18 in rheumatoid arthritis. Ann Rheum Dis 2003, 62(Suppl. II): ii48-ii50.
62. Ishida, Y., Kondo, T., Takayasu, T. et al. The essential involvement of cross-talk between IFN-γ and TGF-β in the skin wound-gealing process. J Immunol 2004. 172(3): 1848-55.
63. Horwood, N.J., Udagawa, N., Elliot, J. et al. Interleukin 18 inhibits osteoclast formation via T cell production of granulocyte macrophage colony-stimulating factor. J Clin Invest 1998, 101(3): 595-603.
64. Jelusic, M., Lukic, I.K., Tambic-Bukovac, L. et al. Interleukin-18 as a mediator of systemic juvenile idiopathic arthritis. Clin Rheum 2007, 26(8): 1332-4.
65. Maeno, N., Takei, S., Nomura, Y. et al. Highly elevated serum levels of interleukin-18 in systemic juvenile idiopathic arthritis but not in other juvenile idiopathic arthritis subtypes or in Kawasaki disease: Comment on the article by Kawashima et al. Arthritis Rheum 2002, 46(9): 2539-41; author reply 2541-2.
66. Wong, C.K., Li, E.K., Ho, C.Y. and Lam, C.W. Elevation of plasma interleukin-18 concetralion id correlated with disease activity in systemic lupus erythematosus. Rheumatology (Oxf.) 2000, 39(10): 1078-81.
67. Gangemi, S., Merendino, R.A., Guarneri, F. et al. Serum levels of interleukin-18 and s-ICAM-1 in patients affected by psoriasis: Preliminary considerations. J Eur Acad Dermatol Venerol 2003, 17: 42-6.
68. Arican, O., Aral, M., Sasmaz, S. and Ciragil, P. Seum levels of TNF-α, IFN-γ, IL-6, IL-S, IL-12, IL-17, and IL-18 in patients with active psoriasis and correlation with disease severity. Mediators Inflamm 2005, 2005(5): 273-79.
69. Firestein, G.S. Evolving concepts of rheumatoid arthritis. Nature 2003. 423(6937): 356-61.
70. Miossec, P. An update on the cytokine network in rheumatoid arthritis. Curr Opin Rheumatol 2004, 16(3): 218-22.
71. Gracie, J.A., Forscy, R.J., Chan, W.L. et al. A proinflammatory role of IL-18 in rheumatoid arthritis. J Clin Invest 1999. 104(10): 1393-401.
72. Tanaka, M., Harigai, M., Kawaguchi, Y. et al. Mature form of interleukin 18 is expressed in rheumatoid arthritis synovial tissue and contributes to interferon-γ production by synovial T cells. J Rheumatol 2001, 28(8): 1779-87.
73. Wei, X.Q., Leung, B.P., Arthur, H.M.. McInnes, I.B. and Liew, F. Y. Reduced incidence and severity of collagen-induced arthritis in mice lacking IL-18. J Immunol 2001, 166(1): 517-21.
74. Kawashima, M., Yamamura, M., Taniai. M. et al. Levels of interleukin-18 and its binding inhibitors in the blood circulation of patients with adult-onset Still's disease. Arthritis Rheum 2001, 44(3): 550-60.
75. Sandler, R.S. and Loftus, E.V. Jr. Epidemiology of inflammatory bowel diseases. In Sartor, R.B., Sandborn, W.J. (Eds.). Kirsner's Inflammatory Bowel Diseases. Elsevier: London 2004, 245-62.
76. Pizarro, T.T., Michie, M.H., Bentz, M. et al. IL-18, a novel immunoregulatory cytokine, is up-regulated in Crohn' 2 disease: Expression and localization in intestinal mucosal cells. J Immunol 1999, 162(11): 6829-35.
77. Monteleone, G., Trapasso, F., Parrello, T et al. Bioactive IL-18 expression is up-regulated in Crohn's disease. J Immunol 1999, 163(1): 143-7.
78. Reuter, B.K. and Pizarro, T.T. Commentary: The role of the IL-18 system and other members of the IL-1R/TLR superfemily in innate mucosal immunity and the pathogenesis of inflammatory bowel disease: Friend of foe? Eur J Immunol 2004, 34(9): 2347-55.
79. Siegmund, B. and Zeitz, M. Therapeutic approaches in inflammatory bowel disease based on the immunopathogenesis. Rocz Akad Med Bialymst 2004, 49: 22-30.
80. Kam, L.Y. and Targan. S.R. Cytokine-based therapies in inflammatory bowel disease. Curr Opin Gastroenterol 1999, 15(4): 302-7.
81. Rothe, H., Jenkins, N.A., Copeland, N.G. et al. Active stage of autoimmune diabetes is associated with the expression of a novel cytokine IGIF, which is located near Idd2. J Clin Invest 1997, 99(3): 469-74.
82. Rothe, H., Hausmann, A., Casteels, K. et al. IL-18 inhibits diabetes development in nonobese diabetic mice by counterregulation of Th1-dependent destructive insuli ns. J Immunol 1999, 163(3): 1230-36.
83. Oikawa, Y., Shimada, A., Kasuga, A. et al. Systemic administration of IL-18 promotes diabetes development in young nonobese diabetic mice. J Immunol 2003. 171(11): 5865-75.
84. Nicoletti, F., Di Marco, R., Papaccio. G. et al. Essential pathogenetic role of endogenous IL-18 in murine diabetes induced by multiple low doses of streplozotocin. Prevention of hyperglycemia and insulilis by recombinant IL-18 binding protein:Fc construct. Eur J Immunol 2003, 33(8): 2278-86.
85. Schott, W.H., Haskell, B.D., Tse, H.M. et al. Caspase-1 is not required for type 1 diabetes in the NOD mouse. Diabetes 2004, 53(1): 99-104.
86. Nicoletti, F., Conget, I., Di Marco, R. et al. Serum levels of the interferon-γ-inducing cytokine interleukin-18 are increased in individuals at high risk of developing type I diabetes. Diabetologia 2001, 44(3): 309-11.
87. Ide, A., Kawasaki, E., Abiru, N. et al. Association between IL-18 gene promoter polymorphisms and CTLA-4 gene 49A/G polymorphism in Japanese patients with type I diabetes. J Autoimmun 2004, 22(1): 73-8.
88. Kretowski, A., Mironczuk, K., Karpinska, A. et al. Interleukin-18 promoter polymorphisms in type 1 diabetes. Diabetes 2002, 51(11): 3347-9.
89. Hunter, S.F. and Rodrigez, M. Multiple sclerosis: A unique immunopathological syndrome of the central nervous system. Springer Semin Immunopathol 1995, 17(1): 89-105.
90. Olsson, T., Zhi, W.W., Hojebcrg, B. et al. Autoreactive T lymphocytes in multiple sclerosis determined by antigen-induced secretion of interferon-γ. J Clin Invest 1990, 86(3): 981-5.
91. Wildbaum, G., Youssef, S., Grabie, N. and Karin, N. Neutralizing antibodies to IFN-γ-inducing factor prevent experimental autoimmune encephalomyelitis. J Immunol 1998, 161(11): 6368-74.
92. Jander, S. and Stoll, G. Differential induction of interleukin-12, interleukin-18, and interleukin-1β converting enzyme mRNA in experimental autoimmune encephalomyelitis of the Lewis rat. J Neuroimmunol 1998, 91(1-2): 93-9.
93. Shevach, E.M., Chang, J.T. and Segal, B.M. The critical role of IL-12 and IL-12Rβ2 subunit in the generation of pathogenic autoreactive Th1 cells. Springer Semin Immunopathol 1999. 21(3): 249-62.
94. Leonard, J.P.. Waldburger, K.E. and Goldman, S.J. Prevention of experimental autoimmune encephalomyelitis by anti-bodies against interleukin 12. J Exp Med 1995, 181(1): 381-6.
95. Furlan, R., Martino, G., Galbiati, F. et al. Caspase-1 regulates the inflammatory process leading to autoimmune demyelinalion. J Immunol 1999, 163(5): 2403-9.
96. Furlan, R., Filippi, M., Bergami. A. et al. Peripheral levels of caspase-1 mRNA correlate with disease activity in patients with multiple sclerosis: A preliminary study. J Neurol Neurosurg Psychiatry 1999, 67(6): 785-8.
97. Cervera, R., Khamasahta, M.A., Font, J. et al. Systemic lupus erythematosus: Clinical and immunologic patterns of disease expression in a cohort of 1000 patients. The European Working party on systemic lupus erythematosus. Medicine (Baltimore) 1993, 72(2): 113-24.
98. Esfandiari, E., McInnes, I.B., Lindop, G. et al. A proinflammatory role of IL-18 in the development of spontaneous autoimmuine disease. J Immunol 2001, 167(9): 5338-47.
99. Calvani, N., Richards, H.B., Tucci, M., Pannarale, G. and Silvestris, F. Up-regulation of IL-18 and predominance of a Th1 immune response is a hallmark of lupus nephritis. Clin Exp Immunol 2004, 138(1): 171-8.
100. Faust, J., Menke, J., Kriegsmann, J. et al. Correlation of renal tubular epithelial cell-derived interleukin-18 up-regulation with disease activity in MRL-Faslpr mice with autoimmune lupus nephritis. Arthritis Rheum 2002, 46(11): 3083-95.
101. Wong, C.K., Ho, C.Y., Li, E.k., Tarn, L.S. and Law, C.W. Elevated production of interleukin-18 is associated with renal disease in patients with systemic lupus erythematosus. Clin Exp Immunol 2002, 130(2): 345-51.
102. Wong, C.K., Ho, C.y., Ko, F.w. et al. Proinflammatory cytokines (IL-17, IL-6, IL-18 and IL-12) and Th cytokines (IFN-γ, IL-4, IL-I0 and IL-13) in patients with allergic asthma. Clin Exp Immunol 2001, 125(2): 177-83.
103. Tanaka, H., Miyazaki, N., Oashi, K. et al. IL-18 might reflect disease activity in mild and moderate asthma exacerbation. J Allergy Clin Immunol 2001, 107(2): 331-6.
104. Okamoto, I., Kohno, K., Tanimoto, T. et al. IL-18 prevents the development of chronic graft-versus-host disease in mice. J Immunol 2000, 164(11): 6067-74.
105. Hu, H.Z., Li, G.L., Lim, Y.K., Chan, S.H. and Yap, E.H. Kinetics of interferon-γ secretion and its regulatory factors in the early phase of acute graft-versus-host disease. Imunology 1999, 98(3): 379-85.
106. Itoi, H., Fujimori, Y., Tsutsui, H. et al. Fas ligand-induced caspase-I-dependent accumulation of interleukin-18 in mice with acute graft-versus-host disease. Blood 2001, 98(1): 235-7.
107. Fujimori, Y., Takatsuka, H., Takemoto, Y. et al. Elevated interleukin (IL)-18 levels during acute graft-versus-host disease after allogeneic bone marrow transplantation. Br J Haematol 2000, 109(3): 652-7.
108. Zecchina, G., Novick, D., Rubinstein, M. et al. Interleukin-18 binding protein in acute graft versus host disease and engraftment following allogeneic peripheral blood stem cell transplants. J Hematother Stem Cell Res 2001, 10(6): 769-76.
109. Itoi, H., Fujimori, Y., Tsutsui, H. et al. Differential upregulation of interleukin-18 receptor α chain between CD4+ and CDS+ T cells during acute graft-versus-host disease in mice. J Interferon Cytokine Res 2004, 24(5): 291-6.
110. Tsuboi, K., Miyazaki, T., Nakajima, M. et al. Serum interleukin-12 and interleukin-18 levels as a tumor marker in patients with ezophageal carcinoma. Cancer Lett 2004, 205(2): 207-14.
111. Bellone, G., Smirne, C., Mauri, F.A. et al. Cytokine expression profile in human pancreatic carcinoma cells and in surgical specimens: Implications for survival. Cancer Immunol Immunother 2006, 55(6): 684-98.
112. Asakawa, M., Kono, H., Amemiya, H. et al. Role of interleukin-18 and its receptor in hepatocellular carcinoma associated with hepatitis C virus infection. Int J Cancer 2006, 118(3): 564-70.
113. Riedel, F., Adam, S., Feick, P. et al. Manheim Alcohol Study Group. Expression of IL-18 in patients with head and neck squamous cell carcinoma. Int J Mol Med 2004, 13(2): 267-72.
114. Merendino, R.A., Gangemi, S., Ruello, A. et al. Serum levels of Interleukin-18 and slCAM-I in patients affected by breast cancer: Preliminary considerations. Int J Biol Markers 2001, 16(2): 126-29.
115. Akahiro, J., Konno, R., Ito, K. et al. Impact of serum Interleukin-18 level as a prognostic indicator in patients with epithelial ovarian carcinoma. Int J Clin Oncol 2004, 9(1): 42-6.
116. Thalmann, G., Sermier, A., Rentsch, C. et al. Urinary interleukin-8 and 18 predict the response of superficial bladder cancer to intravesical therapy with bacillus Calmette Guerin. J Urol 2000, 164(6): 2129-33.
117. Sozen, S., Coskun, U., Sancak, B. et al. Serum levels of interleukin-18 and nitrite+nitrate in renal cell carcinoma patients with different tumor stage and grade. Neoplasma 2004, 51(1): 25-9.
118. Zhang, B., Wang, Y., Zheng, G.G. et al. Clinical significance of IL-18 gene overexpression in AML. Leuk Res 2002, 26(10): 887-92.
119. Vidal-Vanaclocha, F., Mendoza, L., Telleria, N. et al. Clinical and experimental approaches to the pathophysiology of interleukin-18 in cancer progression. Cancer Metastasis Rev 2006, 25(3): 417-34.
120. Arai, N., Akamatsu, S., Arai, S. et al. Interleukin-18 in combination with IL-2 enhances natural killer cell activity without inducing large amounts of IFN-γ in vivo. J Interferon Cytokine Res 2000, 20(2): 217-24.
121. Osaki, T., Peron, J.M., Cai, Q. et al. IFNγ-inducing factor/IL-18 administration mediates IFNγ- and IL-12-independent anti-tumor effects. J Immunol 1998, 160(4): 1742-49.
122. Yao, N.S., Chen, Y.M., Perng, R.P. and Whang-Peng, J. Additive effect of Interleukin-12 and Interleukin-18 on the T-helper cell pathway of malignant pleural effusion. Lung 2002, 180(1): 15-24.
123. Hegardt, P., Widegren, B., Li, L. et al. Nitric oxide synthase inhibitor and IL-18 enhance the anti-tumor immune response of rats carrying an intrahepatic color carcinoma. Cancer Immunol Immunother 2001, 50(9): 491-501.
124. Merendino, R.A., Ruello, A., Cascinu, S. et al. Influence of 5-fluorouracil and folinic acid on interleukin-18 production in colorectal cancer patients. Int J Biol Markers 2002, 17(1): 63-6.
125. Logan, T.F. and Robertson, M.J. Interleukins 18 and 21 : biology, mechanisms of action, toxicity, and clinical activity. Curr Oncol Rep 2006, 8(2): 114-9.
126. Park, C.C., Morel, J.C., Amin, M.A. et al. Evidence of IL-18 as a novel angiogenic mediator. J Immunol 2001, 167(3): 1644-53.
127. Gerdes, N., Sukhova, G.K., Libby, P. et al. Expression of interleukin (IL)-18 and functional IL-18 receptor on human vascular endothelial cells, and macrophages: Implications for athero-genesis. J Exp Med 2002, 195(2): 245-57.
128. Alexandrakis, M.G., Passam, F.H., Sfiridaki, K. et al. Interleukin-18 in multiple myeloma patients: Serum levels in relation to response to treatment and survival. Leuk Res 2004, 28(3): 259-66.
129. Tsutsui, H., Adachi, K., Seki, E. and Nakanishi, K. Cytokine-induced inflammatory liver injuries. Curr Mol Med 2003, 3(6): 545-59.
130. Han, W.K. and Bonventre, J.V. Biologic markers for the early detection of acute kidney injury. Curr Opin Crit Care 2004, 10(6): 476-82.
131. Caligiuri, G., Kaveri, S. and Nicoletti, A. When interleukin-18 conducts, the Preludio sounds the same no matter who plays. Arterioscler Thromb Vase Biol 2005, 25(4): 655-7.
132. Dinarello, C.A., Novick, D., Rubinstein, M. and Lonnemann, G. Interleukin 18 and interleukin 18 binding protein: Possible role in immunosuppression of chronic renal failure. Blood Purif 2003, 21(3): 258-70.
133. Kim, S.H., Eisenstein, M., Reznikov, L. et al. Structural requirements of six naturally occurring isoforms of the IL-18 binding protein to inhibit IL-18. Proc Natl Acad Sci U S A 2000, 97(3): 1190-5.
134. Novick, D., Kim, S.H., Fantuzzi, G. et al. Interleukin-18 binding protein: a novel modulator of the Th1 cytokine response. Immunity 1999, 10(1): 127-36.
135. Plater-Zyberk, C., Joosten, L.A., Helsen, M.M. et al. Therapeutic effect of neutralizing endogenous IL-18 activity in the collagen-induced model of arthritis. J Clin Invest 2001, 108(12): 1825-32.
136. Banda, N.K., Vondracek, A., Kraus, D. et al. Mechanisms of inhibition of collagen-induced arthritis by murine IL-18 binding protein. J Immunol 2003, 170(4): 2100-5.
137. Sivakumar, P.V., Westrich, G.M., Kanaly, S. et al. Interleukin 18 is a primary mediator of the inflammation associated with dextran sulphate sodium induced colitis: Blocking interleukin 18 attenuates intestinal damage. Gut 2002, 50(6): 812-20.
138. Smeets, R.L., van de Loo, F.A., Amtz, O.J. et al. Adenoviral delivery of IL-18 binding protein C ameliorates collagen-induced arthritis in mice. Gene Ther 2003, 10(12): 1004-11.
139. Siegmund, B., Fantuzzi, G., Rieder, F. et al. Neutralization of interleukin-18 reduces severity in murine colitis and intestinal IFN-γ and TNF-α production. Am J Physiol Regul Integr Comp Physiol 2001 281(4): R1264-73.
140. Zaccone, P., Phillips, J., Conget, I., Cooke, A. and Nicoletti, F. IL-18 binding protein fusion construct delays the development of diabetes in adoptive transfer and cyclophosphamide-induced diabetes in NOD mouse. Clin Immunol 2005, 115(1): 74-9.
141. Braddock, M., Quinn, A. and Canvin, J. Therapeutic potential of targeting IL-1 and IL-18 in inflammation. Expert Opin Biol Ther 2004, 4(6): 847-60.
142. Faubel, S. and Edelstein, C.L. Caspases as drug targets in ischemic organ injury. Curr Drug Targets Immune Endocr Metabol Disord 2005, 5(3): 269-87.
143. Yamin, T.T., Ayala, J.M. and Miller, D.K. Activation of the native 45-kDa precursor form of interleukin-1-converting enzyme. J Biol Chem 1996, 271(22): 13273-82.
144. Dinarello, C.A. Biologic basis for interleukin-1 in disease. Blood 1996, 87(6): 2095-147.
145. Fletcher, D.S., Agarwal, L., Chapman, K.T. et al. A synthetic inhibitor of interleukin-1 β converting enzyme prevents endotoxin-induced interleukin-1 β production in vitro and in vivo. J Interferon Cytokine Res 1995, 15(3): 243-48.
146. Fantuzzi, G. and Dinarello, C.A. The inflammatory response in interleukin-1 β-deficient mice: Comparison with other cytokine-related knock-out mice. J Leukoc Biol 1996, 59(4): 489-93.
147. Fantuzzi, G., Puren, A.J., Harding, M.W., Livingston, D.J. and Dinarello, C.A. Interleukin-18 regulation of interferon γ production and cell proliferation as shown in interleukin-1 β-converting enzyme (caspase-I)-deficient mice. Blood 1998, 91(6): 2118-25.
148. Li, P., Allen, H., Banerjee, S. et al. Mice deficient in IL-1 β-converting enzyme are defective in production of mature IL-1 β and resistant to endotoxic shock. Cell 1995, 80(3): 401-11.
149. Li, P., Allen, H., Banerjee, S. and Seshadri, T. Characterization of mice deficient in interleukin-1 β converting enzyme. J Cell Biochem 1997, 64(1): 27-32.
150. Siegmund, B., Lehr, H.A., Fantuzzi, G. and Dinarello, C.A. IL-1 β-converting enzyme (caspase-1) in intestinal inflammation. Proc Natl Acad Sci U S A 2001, 98(23): 13249-54.
151. Loher, F., Bauer, C., Landauer, N. et al. The interleukin-1 β-converting enzyme inhibitor pralnacasan reduces dextran sulfate sodium-induced murine colitis and T helper 1 T-cell activation. J Pharmacol Exp Ther 2004, 308(2): 583-90.
152. Randle, J.C., Harding, M. W., Ku, G., Schonharting, M. and Kurrle, R. ICE/Caspase-1 inhibitors as novel anti-inflammatory drugs. Expert Opin Investig Drugs 2001, 10(7): 1207-9.
153. Wilson, K.P., Black, J.A., Thomson, J.A. et al. Structure and mechanism of interleukin-1 β converting enzyme. Nature 1994, 370(6487): 270-5.
154. Siegmund, B. and Zeitz, M. Pralnacasan (Vertex Pharmaceuticals). IDrugs 2003, 6(2): 154-8.
155. Garrison, L. and McDonnell, N.D. Etanercept: Therapeutic use in patients with rheumatoid arthritis. Ann Rheum 1999, 58: 165-9.
156. Tsutsui, H., Kayagaki, N., Kuida, K. et al. Caspase-1-independent, Fas/Fas ligand-mediated IL-18 secretion from-macrophages causes acute liver injury in mice. Immunity 1999, 11(3): 359-67.
157. Black, R.A., Kronheim, S.R., Cantrell, M. et al. Generation of biologicallly active interleukin-1 β by proteolitic cleavage of the inactive precursor. J Biol Chem 1988, 263(19): 9437-42.
158. Hazuda, D.J., Strickler, J., Kueppers, F., Simon, P.L. and Young, P.R. Processing of precrsor interleukin 1 β and inflammatory disease. J Biol Chem 1990, 265(11): 6318-22.
159. Irmler, M., Hertig. S., MacDonald, H.R. et al. Granzyme A is an interleukin 1 β-converting enzyme. J Exp Med 1995, 181(5): 1917-22.
160. Mizutani, H., Schechter, N., Lazarus, G., Black, R.A. and Kupper, T.S. Rapid and specific conversion of precursor interleukin 1 β (IL-1 β) to an active IL-1 species by human mast cell chymase. J Exp Med 1991, 174(4): 821-25.
161. Ferrari, D., Pizzirani, C., Adinolfi, E. et al. The P2X7 receptor: A key player in IL-1 processing and release. J Immunol 2006, 176(7): 3877-83.
162. Chen, Y.W., Donnelly-Roberts, D.L., Namovic, M.T. et al. Pharmacological characterization of P2X7 receptors in rat peritoneal cells. Inflamm Res 2005, 54(3): 119-26.
163. Mehta, V.B., Hart, J. and Wewers, M.D. ATP-stimulaled release of interleukin (IL)-1β and IL-18 requires primind by lipopolysaccharide and is independent of caspase-1 cleavage. J Biol Chem 2001, 276(6): 3820-6.
164. Perregaux, D.G., McNiff, P., Laliberte, R., Conklyn, M. and Gabel, C.A. ATP acts as an agonist to promote stimulus-induced secretion of IL-1β and IL-18 in human blood. J Immunol 2000, 165(8): 4615-23.
165. Rampe, D., Wang, L. and Ringheim, G.E. P2X7 receptor modulation of β-amyloid-and LPS-induced cytokine secretion from human macrophages and microglia. J Neuroimmunol 2004, 147(1-2): 56-61.
166. Sudo, N., Tanaka, K., Koga, Y. et al. Extracellular ATP activates mast cells via a mechanism different from the activation induced by cross-linking of Fc receptors. J Immunol 1996, 156(10): 3970-9.
167. 7: Cloning and expression of a human cDNA. J Biol Chem 1997, 272(9): 5482-6.
168. 7 nucleotide receptor mediation of membrane pore formation in human promyelocytes and neutrophyls. J Immunol 2001, 166(11): 6754-63.
169. 7 receptor. Neuropharmacol 1997, 36: 1277-83.
170. Sluyter, R., Barden, J.A. and Wiley, J.S. Detection of P2X purinergic receptors of human B lymphocytes. Cell Tissue Res 2001, 304(2): 231-6.
171. 7 receptor in immune cells of the brain and periphery. J Biol Chem 2001, 276(26): 23262-7.
172. 7 purinergic receptor: Characterization and possible participation inantigen presentation. J Immunol 1999, 163(4): 1958-65.
173. Solle, M., Labasi, J., Perregaux. D.G. et al. Altered cytokine production in mice lacking P2X(7) receptors. J Biol Chem 2001, 276(1): 125-32.
174. Labasi, J.M., Petrushova, N., Donovan, C. et al. Absence of the P2X7 receptor alters leukocyte function and attenuates an inflammatory response. J Immunol 2002, 168(12): 6436-45.
175. Dell'Antonio, G., Quattrini, A., Cin, E.D., Fulgenzi, A. and Ferrero, M.E. Relief of inflammatory pain in rats by local use of the selective P2X7 ATP receptor inhibitor, oxidized ATP. Arthritis Rheum 2002, 46(12): 3378-85.
176. Dell'Antonio, G., Quattrini, A., Dal Cin, E., Fulgenzi, A. and Ferrero, M.E. Antinociceptive effect of a new P(2Z)/P2X7 antagonist, oxidized ATP. in arthritic rats. Neurosci Lett 2002, 327(2): 87-90.